Key MessageQuestion: Is immunotherapy efficient in patients with lung cancer and harboring an oncogenic addiction?Findings: Patients' outcome treated with ICI monotherapy were consistent with ICI registration trials in the KRAS-subgroup but were inferior for patients with actionable driver mutations.Meaning: ICI should thus only be considered after exhaustion of targeted and standard therapies.Alt-text: Unlabelled Box

Introduction {#s0015}
============

The management of patients with stage 4 non-small-cell lung cancer (NSCLC) is currently undergoing significant transformation. Molecular testing, targeted therapies, and immunotherapy are now part of routine clinical care \[[@bb0010]\]. Targeted therapies are efficient in the context of oncogenic driver mutations \[[@bb0015]\]. These treatments are associated not only with high response rate, but also with unavoidable development of resistance and tumor recurrence \[[@bb0020]\]. Therapeutic options are restrained in patients after exhaustion of targeted therapies and chemotherapy. Immune checkpoint inhibitors (ICI) that block the programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) axis is a new standard of care \[[@bb0025], [@bb0030], [@bb0035]\]. ICI response rates in general are ∼20% in unselected NSCLC, but overall survival (OS) benefit was well documented in registration trials \[[@bb0040], [@bb0045], [@bb0050], [@bb0055]\].

Whether ICIs alone or even in combination with TKIs would offer comparable benefit in oncogene addicted subtypes of NSCLC as much as in the general unselected NSCLC population has been raised as a relevant question \[[@bb0060]\]. We may expect that immunotherapy may transform the important tumor responses achieved with targeted inhibitors in prolonged remissions. Nevertheless, data obtained from subgroups in clinical trials \[[@bb0050], [@bb0055], [@bb0065]\] and from investigators observations have shown rather weak activity of ICI in NSCLC patients harboring actionable driver mutations \[[@bb0070]\]. Therefore, the optimal use of ICI therapy in patients with actionable driver mutations remains an important field of ongoing research.

The purpose of this study was to analyze the clinical activity of ICI therapy in the context of oncogenic driver alterations. We previously conducted registry studies on targeted therapies for NSCLC with *ROS1*, *HER2*, *BRAF*, and *RET* alterations \[[@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095]\]. We used our established network to perform a wide international cohort of patients with molecularly defined NSCLC. Hereinafter, we present the results for the whole cohort, and for individual molecular subgroups.

Patients and methods {#s0020}
====================

Study objectives {#s0025}
----------------

The primary objective of our study was to describe the progression-free survival (PFS) of patients treated with PD1/PD-L1 checkpoint inhibitors (ICI) in each subgroup carrying an oncogenic driver. The secondary objectives were both the best overall response (that was not confirmed by a second measurement) and the OS for each molecular subgroup. We also analyzed the outcome of patients according to smoking status, line of treatment, and PD-L1 expression.

Patients' selection {#s0030}
-------------------

A global multicenter network of thoracic oncologists accrued patients in this registry. Investigators were identified via an ongoing collaboration established by our prior registries \[[@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095]\]. Eligible patients had (i) a pathologic diagnosis of lung cancer; (ii) local testing positive (either direct sequencing or NGS on validated platforms) for at least one oncogenic driver mutation: *EGFR* (exon 18--21) activating mutation, *HER2* (*exon 20*) activating mutation, *KRAS* mutation, *BRAF* (exon 15) mutation, *MET* amplification or exon 14 mutation, *ALK* rearrangement, *ROS1* rearrangement or *RET* rearrangement; (iii) single agent ICI therapy with commercial anti-PD1/PD-L1-antibodies; (iv) local response assessment according to RECIST1.1 criteria; (v) follow-up with survival status. Optionally, investigators were asked to record immunotherapy-related adverse events (irAE) and PD-L1 expression in tumor cells.

PD-L1 analysis {#s0035}
--------------

PD-L1 analysis was carried out in each center according to local procedures. Antibodies used were E1L3N (32.8%), SP142 (31.7%), 22C3 (22.2%), SP263 (6.7%), 28-8 (5.6%), and others (1.1%). Results were provided in percentage of staining of tumor cells with three cut-off levels: 1%, 10%, and 50%.

Ethical considerations {#s0040}
----------------------

The study was approved by the national ethics committees of France (CEPRO 2017-043, CNIL Nh22181405I) and Switzerland (Swissethics/EKNZ ID 2017-01530). Participating centers were responsible for patients' consent and institutional approval. All contributors were trained in Good Clinical Practice. The study was a purely academic collaboration granted by both Toulouse and Lucerne Hospitals and was not funded by industry.

Data collection and response assessment {#s0045}
---------------------------------------

Anonymized clinical data were recorded by local investigators using electronic case report forms (eCRF) in a password-protected secure online portal from the University of Toulouse (<https://ec.claudiusregaud.fr/CSOnline/>). Data were centrally collected at the University of Toulouse (France). The registry was open for enrollment from May 2017 until April 2018. Best response to systemic therapies, defined as a complete or partial response achieved at least once during the course of therapy, was assessed locally using RECIST v1.1 criteria.

Statistical methods {#s0050}
-------------------

All statistical evaluations were carried out according to the predefined plan as stated in the protocol. Data were summarized according to frequency and percentage for qualitative variables, and by median and range for quantitative variables. The 95% confidence interval for response rate was calculated using the exact binomial distribution. PFS was measured as the time from the first administration of ICI therapy to progression defined by RECIST1.1, or death due to any cause. Patients alive without progression at the time of analysis were censored at the initiation of a new therapy or last follow-up. OS was measured as the time from the first administration of ICI therapy to death due to any cause. Patients alive at the time of analysis were censored at the last follow-up. Survival data were estimated using the Kaplan--Meier method and compared using the log-rank test in overall cohort and oncogenic driver subgroups. Statistical analyses were carried out using STATA 13.1 software (StataCorp, TX).

Results {#s0055}
=======

Patients' characteristics {#s0060}
-------------------------

During an enrollment phase of almost 1 year, the registry included 551 patients from 24 centers in 10 countries. The molecular alterations involved *KRAS* (*n* = 271), *EGFR* (*n* = 125), *BRAF* (*n* = 43, *V600En* = 17, other *n* = 18), *MET* (*n* = 36, *MET* amplification *n* = 13, exon 14 skipping mutation *n* = 23), *HER2* (*n* = 29), *ALK* (*n* = 23), *RET* (*n* = 16), and *ROS1* (*n* = 7). A total of 34 patients with more than 1 driver were allocated to the dominant oncogenic driver. Details are provided in the [supplementary Figure S1 and S2, available at Annals of Oncology online](#ec0010){ref-type="fig"}. Median age was 60 years (range 29--83). Gender ratio was 1 : 1. Smoking status was 28% never smokers, 51% former smokers, and 21% current smokers. The majority (96%) of tumors were adenocarcinoma. At the time of immunotherapy initiation, most patients had ECOG performance status (PS) of 1 (64%), while fewer patients were PS0 (21%), PS2 (11%), and PS3/4 (4%). All patients presented an advanced tumor stage at the beginning of immunotherapy. The clinical characteristics of each subgroup are reported in [Table 1](#t0010){ref-type="table"}.Supplementary DataSupplementary DataSupplementary DataTable 1Clinical and biological description according to mutation typeTable 1EGFRKRASALKBRAFROS1HER2RETMET*N* = 125*N* = 271*N* = 23*N* = 43*N* = 7*N* = 29*N* = 16*N* = 36Gender (*n*=551) Male4838.4%14152%1252.2%2455.8%571.4%1551.7%743.8%2158.3% Female7761.6%13048%1147.8%1944.2%228.6%1448.3%956.3%1541.7%Smoking (*n*=551) Never smoker7863.4%124.6%1047.6%1126.2%571.4%1451.9%1066.7%823.5% Former smoker3830.9%16864.6%838.1%2252.4%228.6%1244.4%426.7%1544.1% Current smoker75.7%8030.8%314.3%921.4%00%13.7%16.7%1132.4% Missing21121212Histological type (*n*=551) Adenocarcinoma12196.8%26296.7%2191.3%4093%685.7%2896.6%1487.5%3494.4% Squamous10.8%00%00%12.3%00%00%00%00% Sarcomatoid00%10.4%00%00%00%00%00%12.8% Large cell carcinoma00%62.2%14.3%12.3%00%13.4%16.3%00% Not specified/other/missing32.4%20.7%14.3%12.3%114.3%00%16.3%12.8%Age at diagnosis (*n*=551) Median (year)60595561456254.563 Range (year)33--8030--8330--7342--7542--6731--7729--734--82

Treatment characteristics and safety {#s0065}
------------------------------------

Most (94%) patients received anti-PD1-antibodies (nivolumab *n* = 466, pembrolizumab *n* = 48, other *n* = 6), fewer patients (6%) had anti-PD-L1-antibodies (atezolizumab *n* = 19, durvalumab *n* = 11, other *n* = 1). ICIs were given in the first (5%), second (41%), third (26%), fourth line (13%) or in later lines (14%) of treatment ([supplementary Table S3, available at Annals of Oncology online](#ec0010){ref-type="fig"}). The recording of significant (grades 3 and 4) irAE was optional. From 462 patients with available data, 50 (10.8%) had grade 3--5 irAEs, including 36 (7.8%) of grade 3, 13 (2.8%) of grade 4, and 1 of grade 5 (0.2%, endocrine disorder). The pneumonitis rate was in the expected range (13 cases, 2.8% including 8 grade 3 and 5 grade 4). No unexpected irAEs were recorded.

PD-L1 expression {#s0070}
----------------

PD-L1 status was available for 214 patients. The median number of positive cells was 10%. Using a 1% cut-off, one-third was negative (33.2%) and two-third was positive (66.8%). Using a 10% cut-off, half of the tumors was negative (49.7%) and half positive (50.3%). Using a 50% cut-off, one-third of the tumors was positive (33.9%). Looking into each subgroup, we found that median percentage of cells expressing PD-L1 was 0 in *HER2* (*n* = 13), 3.5 in *EGFR* (*n* = 38), 7.5 in *ALK* (*n* = 10), 12.5 in *KRAS* (*n* = 80), 26 in *RET* (*n* = 6), 30 in *MET* (*n* = 15), 50 in *BRAF* (*n* = 9), and 90 in *ROS1* (*n* = 5) subgroups ([supplementary Table S4](#ec0010){ref-type="fig"} and [Supplementary Figure S5, available at Annals of Oncology online](#ec0010){ref-type="fig"}).

Clinical outcomes {#s0075}
-----------------

### Response rate {#s0080}

The rate of any partial or complete response was 19% \[95% CI 16% to 23%\], ranging from 0% in ALK patients to 26% in KRAS-mutated patients. If we consider the KRAS patients as a control group and exclude them from the analysis, the best response rate for patients harboring all other molecular alterations was 12.7%. We then classified the subgroups according to the rate of progressive disease (PD). PD was observed in 46% for *BRAF*, 50% for *MET*, 51% for *KRAS*, 67% for *HER2*, 67% for *EGFR*, 68% for *ALK*, 75% for *RET*, and 83% for *ROS1*. ([Figure 1](#f0010){ref-type="fig"}; [supplementary Table S6, available at Annals of Oncology online](#ec0010){ref-type="fig"}). Details according to the mutation subtype are in [supplementary Table S7, available at Annals of Oncology online](#ec0010){ref-type="fig"}.Figure 1Best response to ICI according to RECIST criteria (PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response).Figure 1

### Overall survival {#s0085}

In the entire cohort, median follow-up was 16.1 months, and median OS from start of ICI therapy was 13.3 months \[10.0--14.9\] ([Figure 2](#f0015){ref-type="fig"}). Median OS (in months) for individual molecular subgroups was 10.0 \[6.7; 14.2\] for *EGFR* mutated patients, 13.5 \[9.4; 15.6\] for *KRAS*, 17.0 \[3.6; NR\] for *ALK*, 13.6 \[7.4; 22.5\] for *BRAF*, 20.3 \[7.8; NR\] for *HER2*, 21.3 \[3.8; 28.0\] for *RET*, and 18.4 \[7.0; NR\] for *MET* ([supplementary data S7, available at Annals of Oncology online](#ec0010){ref-type="fig"}). In the univariate analysis, OS did not correlate with gender, age, smoking, number of prior therapies, or PD-L1 expression ([supplementary Table S8, available at Annals of Oncology online](#ec0010){ref-type="fig"}).Figure 2Overall survival (on the left) and progression-free survival (on the right) in the whole cohort (upper figures) and in each subgroup (lower figures).Figure 2

### Progression-free survival {#s0090}

In the entire cohort, median PFS was 2.8 months \[95% CI 2.5--3.1\]. Median PFS (in months) for individual molecular subgroups was 2.1 \[1.8; 2.7\] for *EGFR*, 3.2 \[2.7; 4.5\] for *KRAS*, 2.5 \[1.5; 3.7\] for *ALK*, 3.1 \[1.8; 4.6\] for *BRAF*, 2.5 \[1.8; 3.5\] for *HER2*, 2.1 \[1.3; 4.7\] for *RET*, and 3.4 \[1.7; 6.2\] for *MET* ([Figure 2](#f0015){ref-type="fig"}). Long-term responders were more frequent in *KRAS* (12 months PFS: 25.6%), *MET* (23.4%), and *BRAF* (18.0%) subgroups, than in *EGFR* (6.4%), *ALK* (5.9%), *HER2* (13.6%), and *RET* (7.0%) subgroups ([Table 2](#t0015){ref-type="table"}). If we exclude *KRAS* patients from the analysis (*n* = 279 patients with all other alterations), median PFS was 2.4 months.Table 2PFS according to primary oncogenic driver from initiation of ICITable 2EVT/*N*Median PFS \[95% CI\] (months)6-month PFS \[95% CI\]12-month PFS \[95% CI\]KRAS208/2713.2 \[2.7; 4.5\]37.9 \[32.1; 49.8\]25.6 \[20.2; 31.3\]EGFR117/1252.1 \[1.8; 2.7\]18.4 \[12.1; 25.6\]6.4 \[2.7; 12.1\]BRAF34/433.1 \[1.8; 4.6\]32.1 \[18.3; 46.6\]18.0 \[7.2; 32.7\]HER223/292.5 \[1.8; 3.5\]22.7 \[8.9; 40.2\]13.6 \[3.6; 30.1\]MET26/363.4 \[1.7; 6.2\]36.5 \[20.7; 52.4\]23.4 \[10.6; 39.0\]ALK21/232.5 \[1.5; 3.7\]11.8 \[2.2; 30.2\]5.9 \[ 0.4; 23.0\]ROS1--------RET15/162.1 \[1.3; 4.7\]14.1 \[2.3; 35.9\]7.0 \[0.4; 27.1\][^1]

In the univariate analysis, PFS significantly correlated with smoking (median PFS: 2.5, 2.8, and 3.5 months for never smokers, former smokers, and current smokers, respectively, *P *\< 0.0001), and with PD-L1 expression (3.0 versus 4.2 months for negative and positive expression of PD-L1, *P *= 0.02). However, PFS did not correlate with gender (*P *= 0.5), age (*P *= 0.3), or number of previous lines of treatment (*P *= 0.08) ([supplementary Table S9 and S10, available at Annals of Oncology online](#ec0010){ref-type="fig"}). Interestingly, a higher rate of rapid progression (within 2 months) was observed for EGFR (44.8%), ALK (45.5%), ROS1 (42.9%), and RET (43.8%) patients than for KRAS (36%) ([supplementary Table S11, available at Annals of Oncology online](#ec0010){ref-type="fig"}), respectively.

Molecular subgroup analyses {#s0095}
---------------------------

*KRAS* mutations were identified in 271 patients. PFS was not significantly different regarding *KRAS* mutation subtype if we compare *G12C* (*n* = 100) to other mutations (*n* = 143, *P *= 0.47) or *G12D* (*n* = 39) versus other *KRAS* mutations (*n* = 204, *P *= 0.40). PFS did also not correlate with smoking (*P *= 0.98), or with the number of previous lines of treatment. In patients with available PD-L1 expression data (*n* = 95), PD-L1 positive expression was significantly (*P *= 0.01) correlated with a longer PFS (median PFS: 7.2 versus 3.9 months) ([Figure 3](#f0020){ref-type="fig"}). We also separate patients harboring *KRAS* transition (G12D, G13D, G12S) from *KRAS* transversion (G12C, G12A, G12V, G13C). PFS was not impacted by the nature of *KRAS* alteration (2.9 months for transition, 4.0 for transversion, *P* = 0.27; [supplementary Table S12, available at Annals of Oncology online](#ec0010){ref-type="fig"}).Figure 3PFS according to oncogenic drivers' variants and PDL1 expression.Figure 3

PFS was significantly different across *EGFR* molecular subgroups ranging from 1.4 month in *T790M* and complex mutations subgroup to 1.8 for exon 19, 2.5 for exon 21, and 2.8 for other mutations (*P *\< 0.001). PFS correlated neither with smoking (*P *= 0.06), nor with the number of previous lines of treatment. PD-L1 positivity was significantly correlated with a longer PFS (2.8 months versus 1.7, *P* = 0.01) ([Figure 3](#f0020){ref-type="fig"}).

For *BRAF* patients, PFS was significantly higher in smokers versus never smokers (4.1 versus 1.9 months, *P *= 0.03). Median PFS was numerically shorter in the V600E subgroup (1.8 months) compared with other *BRAF* mutations (4.1 months, *P *= 0.20).

*MET* molecular alterations were found in 36 patients. Median PFS correlated neither with alteration subtype (exon 14 skipping mutation versus other *MET* alterations, *P *= 0.09), nor with smoking.

*HER2* mutations were identified in 29 patients. PFS correlated with smoking (3.4 months for smokers versus 2.0 months for never smokers, *P *= 0.04).

Due to a low number of patients, *ALK*, *ROS1*, and *RET* were analyzed together in a subgroup termed 'rearrangements'. Median PFS was only slightly higher in never smokers (2.6 months) than in smokers (1.8 months, *P *= 0.03). PD-L1 was not available in enough patients but no tumor response was reported in patients from this group in the context of PD-L1 positivity ([supplementary Table S13](#ec0010){ref-type="fig"} and [Supplementary Figure S5](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online). Main results for all cohorts are presented in [supplementary Figure S14, available at Annals of Oncology online](#ec0010){ref-type="fig"}.

Discussion {#s0100}
==========

The standard of care for patients with actionable driver alterations is a targeted therapy. After exhaustion of targeted agents and chemotherapy, immunotherapy may be considered as a salvage treatment. Nevertheless, evidence to support the role of ICI in this setting is controversial, as *EGFR* and *ALK* alterations have been associated with low ICI efficacy in prior studies \[[@bb0100]\]. To address this issue, we conducted a global 'real world' study. Our study was retrospective and had other limitations, including reporting bias, lack of central molecular and radiologic assessment, and variable scanning intervals. Nevertheless, we obtained new findings of clinical relevance.

In the overall cohort, the best response with ICI therapy by RECIST was 19%, and median PFS was 2.8 months. This result was mainly driven by the large KRAS-subgroup, and it is in concordance with registration trials testing immunotherapy in pretreated patients, regardless *EGFR* or *ALK* status \[[@bb0050], [@bb0055]\]. Regarding molecular subgroups, we confirmed that patients with *KRAS*-mutant NSCLC derived a greater benefit from ICI than *EGFR*-mutant NSCLC, as previously reported \[[@bb0050]\]. It has been reported that *KRAS*-mutant NSCLC are more likely to express PD-1 and PD-L1 \[[@bb0105]\]. In our study, we have not been able to detect a significant correlation between *KRAS* mutation subtypes and PFS, but we confirmed that PD-L1 expression is associated with a better outcome. The limited number of patients with available PDL1 status and the heterogeneity of the tests did not allow us to draw a definitive conclusion on its potential interest. Recently, *STK11/LKB1* co-mutation in KRAS-mutant NSCLC was reported as a new predictive marker for tumor resistance to ICI therapy \[[@bb0110]\]. *STK11* was not part of routine testing and our study did not include tissue collection, therefore, future studies will have to validate this interesting finding in a larger cohort. ICI are thus an adequate treatment of *KRAS*-mutated patients.

Concerning patients with *EGFR* mutation, the role of ICI therapy is still controversial. Recent studies showed an inverse relationship between PD-L1 expression and EGFR mutations. Moreover, an uninflamed tumor microenvironment is often reported in the context of oncogenic addiction \[[@bb0115], [@bb0120]\]. Gainor et al. also suggested that a dearth of tumor-infiltrating CD8+ lymphocytes, may explain the low response rate to PD-1 axis inhibitors observed amongst EGFR- and ALK-driven NSCLC \[[@bb0125]\]. A recent meta-analysis including three randomized trials of immunotherapy in TKI-pretreated patients reported that ICI do not improve OS compared with docetaxel in patients with *EGFR*-mutant NSCLC \[[@bb0130]\]. In addition, a recent phase II trial of pembrolizumab in TKI-naive patients with PD-L1 positive *EGFR*-mutant NSCLC showed no RECIST responses in the first 11 patients \[[@bb0135]\]. In the phase II trial ATLANTIC of durvalumab in EGFR/ALK mutant NSCLC, response rate was 3.6% for PD-L1 \<25%, and 12.2% for PD-L1 \>25%. Median PFS was 1.9 month \[[@bb0100]\]. Benefit has, however, been reported in patients with EGFR mutations with the combination of carboplatin, paclitaxel, bevacizumab, and atezolizumab in the IMpower150 trial \[[@bb0030]\].

*BRAF* mutations were associated with slightly better outcomes compared with *EGFR* mutations (RR 24% and PFS 3.1 months). The potential efficacy of immunotherapy in *BRAF*-mutant melanoma has already been suggested \[[@bb0140]\]. Recently, Dudnik et al. reported frequent expression of PDL1 and comparable PFS (3.7 months) in BRAF V600E-mutated patients \[[@bb0145]\]. In our study, PFS in patients with *BRAF*-mutant NSCLC was positively associated with smoking status. It thus appears that immunotherapy may be considered in *BRAF* positive patients after targeted therapy and one line of chemotherapy.

*ALK*, *ROS1*, and *RET* translocation represent a small subgroup of NSCLC. In our study, PD-L1 expression was relatively high in those cases. However, most tumors were refractory to ICI therapy. These observations were consistent with other studies, namely with ATLANTIC for ALK, and with a cohort study from MSKCC for RET \[[@bb0150]\]. Although these data are preliminary, we do not recommend ICI as single agents in patients with ALK/ROS1/RET rearranged NSCLC.

In conclusion, patients' outcome treated with ICI monotherapy overall were consistent with ICI registration trials, based on the large KRAS-subgroup in our study. However, outcomes for patients with actionable driver mutations (*EGFR, ALK, ROS1*) were inferior and ICI should only be considered after exhaustion of targeted therapies and in some cases, potentially in all other therapies including standard and salvage chemotherapies. We think that there are two ways to optimize the use of immunotherapy in the context of oncogenic addiction. The first one is to combine immunotherapy with other drugs such as chemotherapy and antiangiogenic agents. The second one is to identify new relevant biomarkers besides PD-L1 expression and TMB considering the complex molecular biology of NSCLC.
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